Aardvark Therapeutics, Inc. AARD 深 沪
等待开盘 12-24 09:30:00 美东时间
14.15
-0.400
-2.75%
华盛通- 最 高15.33
- 今 开15.33
- 成交量 24.03万股
- 最 低 13.87
- 昨 收 14.55
- 总市值 3.08亿
- 52周最高 19.58
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 4.88
- 委 比 20.00%
- 总股本 2177.33万
- 历史最高 19.58
- 量 比 0.63
- 振 幅 10.03%
- 历史最低 4.88
- 每 手 1
- 风险率 2.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Oppenheimer Initiates Coverage On Aardvark Therapeutics with Outperform Rating, Announces Price Target of $35
Oppenheimer analyst Leland Gershell initiates coverage on Aardvark Therapeutics (NASDAQ:AARD) with a Outperform rating and announces Price Target of $35.
12-23 19:40
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst
Aardvark Therapeutics gains an Outperform rating as its Phase 3 PWS trial progresses and analysts point to large market potential for ARD-101 and ARD-201.
12-13 03:04
Aardvark Therapeutics Doses First Patient In Australia In HERO Phase 3 Trial For Prader-Willi Syndrome
Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readoutClinical trial sites in Canada and the United Kingdom have received regulatory clearance to enrollAll patients who
12-11 05:38
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
RBC Capital Maintains Outperform on Aardvark Therapeutics, Lowers Price Target to $18
RBC Capital analyst Brian Abrahams maintains Aardvark Therapeutics (NASDAQ:AARD) with a Outperform and lowers the price target from $19 to $18.
11-14 23:37
Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.80) by 6.72 percent. This is a 28.57 percent increase over losses of $(1.05) per share
11-14 05:32
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Aardvark Therapeutics Presents Data At ObesityWeek 2025 Demonstrating Mechanistic Rationale And Therapeutic Potential Of Two Metabolic Obesity Programs, Including ARD-201
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today's obesity treatment
11-05 01:02
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek
Aardvark Therapeutics will host an investor webinar on November 5, 2025, to discuss data from ObesityWeek 2025, including ARD-101, ARD-201, and WE-868, and their potential in treating metabolic diseases. The webinar will also cover ARD-101 in Prader-Willi Syndrome. ARD-101, a gut-restricted TAS2R agonist, reduces hunger and is in Phase 3 trials for hyperphagia in PWS. ARD-201, a fixed-dose combination of ARD-101 and a DPP-4 inhibitor, aims to enh...
10-22 12:00
